HCPCS Level II code J0257 identifies the injectable human alpha-1 proteinase inhibitor product Glassia, billed per 10 mg unit. This biologic replacement therapy is used for augmentation in patients with alpha-1 antitrypsin deficiency and is typically administered in hospital outpatient departments, infusion centers, or physician offices. The code matters nationally because biologic therapies for rare conditions drive specialty drug spending, influence site-of-care decisions, and require specific coverage and medical necessity documentation.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding context, typical sites of service, and common billing considerations for administration of J0257. The publication summarizes benchmark elements relevant to specialty drug billing—unitization, infusion-related service lines, and payer coverage patterns—and highlights areas where policy updates or payer edits commonly affect reimbursement and prior authorization requirements.

The report also provides clinical context for use of alpha-1 proteinase inhibitor replacement, operational implications for infusion delivery, and a clear list of what is and is not available from the input data. Data not available in the input includes specific associated taxonomies, ICD-10 diagnoses, related codes, and service-line details beyond the described product.